The invention relates to Bis-thiol compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating, managing or lessening the severity of pulmonary infections in a subject, the method comprising administering to the subject a bismuth-thiol (BT) composition that comprises at least one BT compound.

The present application relates to 6′-methoxycinchonan-9-ols for use in the prevention or treatment of a coronaviral infection. Pharmaceutical compositions, combinations with antiviral agents, advantageous formulation techniques and a method of treatment are disclosed. Compositions of dietary supplements containing quinine are provided.

The present invention is directed to compositions for administration of camostat mesylate or nafamostat mesylate to subjects by inhalational delivery, and to methods of treatment of COVID19 by administering such compositions to subjects by inhalational delivery.

Methods for treating cough, chronic cough and urges to cough associated with respiratory diseases with a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of Formula (I): ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1 and R.sup.2 are as defined herein.

Devices, compositions, and methods are provided for inhibiting an inflammatory, fibrotic, and/or clot formation for pulmonary disease or condition in a patient. A therapeutic composition comprising a direct factor Xa inhibitor and/or a direct factor IIa inhibitor is provided. A therapeutically effective dose of the therapeutic composition is delivered to a site of the inflammatory, fibrotic, and/or clot formation pulmonary disease or condition in the patient's lung(s). The therapeutic composition may be formulated for delivery to the patient by inhalation, ventilation, instillation, ultrasound, vibration, injection, or the like. The therapeutic composition may include one or more additional therapeutically active substances and/or one or more additional pharmaceutical agents. The one or more additional therapeutically active substances and/or one or more additional pharmaceutical agents may be delivered together with the direct factor Xa inhibitor and/or direct factor IIa inhibitor or separately from the direct factor Xa inhibitor and/or factor IIa inhibitor.

The present disclosure is directed to a liquid composition containing nicotine derived from non-tobacco nicotine sources for use with electronic vaporizing devices. The present disclosure is also directed to electronic vaporizing devices for using such composition. In one embodiment, the liquid compositions are water-based and are substantially free of propylene glycol and vegetable glycerin. In a preferred embodiment, the compositions may be augmented to include additives such as flavorings, medicines, wellness elements, recreational elements, and emulsifiers.

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

The liquid composition includes a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The injectable psychoactive alkaloid composition includes a carrier, an optional tonicity modifier, an optional antioxidant or preservative, an optional pH modifier, and optional further excipients. A process for obtaining an injectable psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid, and standardizing it to a specific concentration by adding measured quantities of excipients.

The present disclosure relates to a pharmaceutical composition comprising an inhalable immunosuppressive macrocyclic active ingredient for use in the prevention or treatment of a pulmonary disease or condition in a subject, wherein the pharmaceutical composition is administered to the subject by inhalation in form of an aerosol, and wherein the aerosol is generated by nebulization of the pharmaceutical composition using a nebulizer (100), the nebulizer comprising: a) an aerosol generator (101) comprising: —a fluid reservoir (103) for holding the pharmaceutical composition or an interface configured to connect a fluid reservoir, and a vibratable membrane (110) having a plurality of apertures, the apertures being adapted to produce an aerosol comprising droplets having a mass median aerodynamic diameter (MMAD) of up to about 4.0 gm as measured with a 0.9% (w/v) aqueous solution of sodium chloride; b) a chamber (105) for temporarily accommodating the aerosol generated by the aerosol generator (101), the chamber having an inner lumen with a volume in the range of from about 50 to about 150 ml; and c) a mouthpiece (40) for delivering the aerosol supplied by the nebulizer (100) to the subject, the mouthpiece having an exhalation filter (30).

Compounds of formula (I), wherein A, R, W, Q, n, and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease. ##STR00001##